Journal
ONCOLOGY AND THERAPY
Volume 7, Issue 2, Pages 101-120Publisher
SPRINGER
DOI: 10.1007/s40487-019-0096-8
Keywords
Checkpoint inhibitor; CTLA-4; Immune-related adverse events (irAEs); Ipilimumab; Melanoma; Nivolumab; PD-1; Pembrolizumab; Toxicity
Categories
Ask authors/readers for more resources
The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available